Seward & Kissel LLP represented its client, Amblyotech, Inc., a US-based digital therapeutics company in connection with the sale of the company to Novartis, a leading global healthcare company. After the acquisition, Novartis intends to pursue the development of Amblyotech’s novel digital technology for the treatment of amblyopia, also known as “lazy eye.” Amblyotech’s approach utilizes an active gaming and passive video technology with 3D glasses to train patients’ eyes to work together, yielding a therapeutic effect. After the acquisition, Novartis intends to collaborate with the Research Institute of the McGill University Health Centre (RI-MUHC) and Ubisoft Entertainment SA to continue product development.